Solid Biosciences (NASDAQ:SLDB) Receives “Buy” Rating from Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Solid Biosciences (NASDAQ:SLDB) in a report published on Thursday morning,Benzinga reports. Chardan Capital currently has a $15.00 price target on the stock.

A number of other research analysts have also recently issued reports on SLDB. Needham & Company LLC reissued a “buy” rating and issued a $16.00 target price on shares of Solid Biosciences in a research note on Monday, February 9th. Wedbush reaffirmed an “outperform” rating and set a $14.00 price target on shares of Solid Biosciences in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Solid Biosciences in a report on Thursday, January 22nd. Finally, Citigroup reiterated a “market outperform” rating on shares of Solid Biosciences in a research report on Wednesday, December 17th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.70.

Solid Biosciences Stock Down 0.1%

SLDB opened at $7.71 on Thursday. Solid Biosciences has a 12 month low of $2.41 and a 12 month high of $8.72. The company has a fifty day simple moving average of $6.20 and a 200 day simple moving average of $5.72. The stock has a market cap of $600.69 million, a P/E ratio of -3.10 and a beta of 2.65.

Insider Activity

In other Solid Biosciences news, insider Gabriel Brooks sold 28,335 shares of Solid Biosciences stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $182,477.40. Following the sale, the insider owned 96,708 shares of the company’s stock, valued at $622,799.52. This trade represents a 22.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO David T. Howton sold 37,771 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $6.44, for a total value of $243,245.24. Following the completion of the sale, the chief operating officer owned 116,753 shares in the company, valued at approximately $751,889.32. This trade represents a 24.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 597,672 shares of company stock worth $3,816,546. 1.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Solid Biosciences

Institutional investors have recently bought and sold shares of the company. Legal & General Group Plc grew its stake in shares of Solid Biosciences by 208.6% during the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after acquiring an additional 4,063 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Solid Biosciences by 205.5% in the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock worth $33,000 after purchasing an additional 4,534 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in Solid Biosciences by 142.0% during the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock worth $63,000 after purchasing an additional 5,991 shares during the last quarter. Creative Planning acquired a new position in Solid Biosciences during the second quarter worth $57,000. Finally, Police & Firemen s Retirement System of New Jersey grew its position in Solid Biosciences by 233.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock valued at $74,000 after purchasing an additional 10,585 shares in the last quarter. Institutional investors own 81.46% of the company’s stock.

Solid Biosciences News Roundup

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Interim INSPIRE data shows strong biological activity: company reported ~60% mean microdystrophin expression at Day 90 across dosed patients, DAPC restoration and signal of cardiac benefit (LVEF). The update emphasizes a consistent mechanistic effect and tolerability in 40 participants, supporting clinical credibility for SGT‑003. Seeking Alpha: Interim Data Lends Credibility
• Positive Sentiment: Company press release reiterates positive interim results, plans additional FDA meetings in H1 2026 to discuss a potential accelerated approval pathway, and expects a mid‑2026 update — this provides a clear near‑term regulatory catalyst to monitor. GlobeNewswire: Interim Clinical Update
• Positive Sentiment: Cash runway extended by a recent $240M private placement, reducing near‑term financing risk and supporting development milestones through 2027 — this materially de‑risks the balance sheet while the program advances. Seeking Alpha: Financing Details
• Positive Sentiment: Analysts reaffirm bullish views: Chardan reiterated a Buy with a $15 PT and Wedbush kept an Outperform with a $14 PT — both imply substantial upside vs. current levels and can support investor interest. Benzinga: Analyst Notes
• Neutral Sentiment: Operational note — trading was temporarily halted around the announcement (news pending). Halts are procedural but can coincide with heightened intraday volatility when resumed. Seeking Alpha: Trading Halt / Market Reaction
• Negative Sentiment: Immediate market reaction was negative/volatile — shares fell after the update despite positive data. This suggests some investors are profit‑taking, skeptical of early‑phase readthroughs, or uncertain about regulatory/tolerability risks ahead. Yahoo Finance: Market Reaction
• Negative Sentiment: Key risks remain: early‑phase data can be re‑assessed by markets, longer‑term safety and confirmatory efficacy are still unproven, and regulatory pathways depend on further FDA interactions and data. Investors should expect volatility until confirmatory milestones. Seeking Alpha: Risk Context

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.